(Reuters) - U.S. drugmaker Gilead Sciences Inc (GILD.O) said on Monday it would buy Forty Seven Inc (FTSV.O) for $4.9 billion in cash, helping it add an experimental treatment that targets blood cancer to its portfolio of oncology drugs.

Shares of Forty Seven jumped nearly 62%, trading slightly below the offer price of $95.50 per share. Gilead shares were up 1.1% at $70.1 in premarket trading.

The buyout is one of the largest deals for Gilead after it closed its near $12 billion acquisition for cancer cell therapy maker Kite Pharma in 2017.

Forty Seven’s lead drug, magrolimab, targets CD47, which switches off a “do not eat me” signal expressed by tumor cells that lets them avoid destruction.

CD47 antibodies are a relatively new class of drugs in development for treating cancer, a lucrative but difficult market to enter for drugmakers.

“Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kite’s pipeline of cell therapies for hematological cancers,” Gilead Chief Executive Officer Daniel O’Day said.

more:

https://www.reuters.com/article/us-forty-seven-m-a-gilead-sciences/gilead-to-buy-cancer-drug-developer-forty-seven-for-4-9-billion-idUSKBN20P1PX

https://www.reuters.com/article/us-germany-airport-drone/drone-sighting-stops-flights-landing-and-taking-off-at-frankfurt-airport-idUSKBN20P1O8

China last month revoked the visas of three Wall Street Journal reporters in Beijing after the newspaper declined to apologize for a column with a headline calling China the “real sick man of Asia”. Another reporter with the paper had to leave last year after China declined to renew his visa. One of the State Department officials said the U.S. decision was not particularly linked to the Wall Street Journal case.

“For years, the (Chinese) government has imposed increasingly harsh surveillance, harassment and intimidation against American and other foreign journalists in China,” a senior State Department official told reporters in a briefing.

“There’s a long standing issue here. We’ve been imploring the Chinese for years and years now to improve their treatment of journalists in China. So, this is not linked to any one particular incident,” he said, but added that the expulsion of Journal reporters was a “fairly egregious” example.

Effective March 13, Washington will be capping the number of U.S. based employees of Xinhua News Agency, China Global Television Network, China Radio International, China Daily Distribution Corp to a total of 100, from 160.

https://www.reuters.com/article/us-usa-china-media-state/trump-administration-to-limit-number-of-employees-at-chinese-media-outlets-in-u-s-idUSKBN20P2PR

NEW YORK (AP) — A memoir by Woody Allen, rumored for years and once thought unpublishable in the #MeToo era, is coming out next month.

Grand Central Publishing, a division of Hachette Book Group, announced Monday that the book is called “Apropos of Nothing” and will be released April 7.

“The book is a comprehensive account of his life, both personal and professional, and describes his work in films, theater, television, nightclubs, and print,” according to Grand Central. “Allen also writes of his relationships with family, friends, and the loves of his life.”

Financial terms were not disclosed for the book, which Grand Central quietly acquired a year ago, and a spokesman declined to provide further details about the book’s contents. In addition to the U.S., “Apropos of Nothing” will be released in Canada, Italy, France, Germany and Spain, followed by releases in “countries around the world.” Allen will do “several interviews” for the book, Grand Central announced.

more:

https://apnews.com/7d967ff10f20f05e79edaec9b3b4eed7

https://apnews.com/03fe3d87a8deca63a6f24e9fddb51f0d